Table 2.
Differences between Interim analysis and all randomized sample analysis for MOVe-OUT trial.
| Parameters | Interim analysis N = 775 |
All Randomized sample N = 1433 |
|||
|---|---|---|---|---|---|
| Study groups | Molnupiravir N = 387 |
Placebo N = 388 |
Molnupiravir N = 716 |
Placebo N = 717 |
|
| Baseline demographic & clinical characteristic | Almost similar | Almost similar | Almost similar | Almost similar | |
| Gender | Female, no. (%) | 200 (51.7) | 171 (44.1) | 384 (53.6) | 351 (49.0) |
| Male, no. (%) | 187 (48.3) | 217 (55.9) | 332 (46.4) | 366 (51.0) | |
| Risk of hospitalization or death through day 29 no. (%) | 28 (7.3) | 53 (14.1) | 48 (6.8) | 68 (9.7) | |
| Death | 0 (0) | 8 (2) | 1 (0.1) | 9 (1.3) | |
| Incidence of any AE (%) | 35% | 40% | 30.40% | 33% | |
| Incidence of drug-related AEs (%) | 12% | 11% | 8.00% | 8.40% | |